Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555582 Eye treatments using synthetic thyroid hormone compositions
04/29/2003US6555570 Growth hormone secretagogous with improved bioavailability
04/29/2003US6555551 E.g. enalapril maleate, by mixing an Angiotensin Converting Enzyme (ACE) inhibitor with an alcohol, adding an aqueous solution of a metal compound, mixing to clarity, blending an excipient to form granulate, drying, adding lubricant
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555522 Peptides and other small molecules derived from regions of interacting proteins and uses thereof
04/29/2003US6555521 From a crystallization solution comprising a GLP, a buffering agent, an alcohol or a mono or disaccharide, and optionally, ammonium sulfate or zinc.
04/29/2003US6555520 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and immunologicval disorders
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555373 Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof
04/29/2003US6555347 Human minor vault protein p193
04/29/2003US6555345 Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses
04/29/2003US6555344 Polynucleotides encoding SRE B2 receptor
04/29/2003US6555343 Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
04/29/2003US6555341 Gamma-aminobutyric acid (GABA); stably co-transfected eukaryotic cell line capable of expressing a human GABAa receptor which comprises a theta receptor subunit and at least one receptor subunit; drug screening
04/29/2003US6555340 Receptor for advanced glycation endproduct (RAGE); nucleic acid, vector and host cell; use in field of drug screening
04/29/2003US6555339 Altering human G protein-coupled receptors (GPCRs) by point mutation; use in drug screening
04/29/2003US6555338 Given nucleotide sequence; use of polynucleotides and polypeptides in diagnostic assays, and possibly functional genomics
04/29/2003US6555321 Methods for determining cell responses through EphB receptors
04/29/2003US6555319 Antibodies for inhibiting blood coagulation and methods of use thereof
04/29/2003US6555156 Process for making absorbable microparticles
04/29/2003US6555138 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances
04/29/2003US6555132 Soft gelatin capsule manufacture
04/29/2003US6555116 Hypo-allergenic pollen protein that has been treated with thioredoxin, nicotinamide adenine dinucleotide phosphate-thioredoxin reductase (NTR) and reduced nicotinamide adenine dinucleotide phosphate (NADPH).
04/29/2003US6555113 Elevating the ratio of circulating HDL to circulating LDL by administering a peptide conjugate of a helper T cell epitope portion linked to a B cell epitope portion; decrease in development of atherosclerotic lesions
04/29/2003US6555112 Peptides derived from the lymphadenopathy-associated virus (LAV) envelope coding region
04/29/2003US6555111 Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies
04/29/2003US6555110 Microencapsulated compounds and method of preparing same
04/29/2003US6555108 Implanting HSV-TK retrovirus producing cells to treat tumors
04/29/2003US6555105 Method of treatment with a RANTES antagonist polypeptide
04/29/2003CA2258502C Modified factor viii
04/29/2003CA2225797C Active principle carriers containing non-ionic surfactants, and uses thereof, particularly in food, cosmetics and pharmaceuticals
04/29/2003CA2159098C Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
04/29/2003CA2121369C Inhibitors of dipeptidyl-aminopeptidase type iv
04/29/2003CA2105804C Kainate-binding, human cns receptors of the eaa5 family
04/29/2003CA2102208C Binding domains in notch and delta proteins
04/29/2003CA2011992C Use of human interferon-beta for stimulation of erythropoiesis
04/25/2003CA2409338A1 Method for protein-preserving purification of contaminated biological liquids
04/24/2003WO2003034791A1 Mounting arrangement for auxiliary burner or lance
04/24/2003WO2003034275A2 Chimeric glycosylphosphatidylinositol containing peptides
04/24/2003WO2003033808A2 Composition and method for treating diabetes
04/24/2003WO2003033738A2 Polymorphic marker that can be used to assess the efficacy of interferon therapy
04/24/2003WO2003033720A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
04/24/2003WO2003033709A2 Regulation of human serine/threonine protein kinase
04/24/2003WO2003033701A1 Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
04/24/2003WO2003033700A1 Method for inhibiting the replication of viruses
04/24/2003WO2003033696A1 Vegf antisense compound
04/24/2003WO2003033689A1 Cloning and recombinant expression of mammalian secreted group iif phopholipase a2
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033677A2 Dimerized growth factor and materials and methods for producing it
04/24/2003WO2003033675A2 Identification of binding partners for specific proteins
04/24/2003WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
04/24/2003WO2003033668A2 Correlation of gene expression with chromosome abnormalities in ataxia telangiectasia tumorigenesis
04/24/2003WO2003033667A2 Use of mx gtpases in the prognosis and treatment of cancer
04/24/2003WO2003033664A2 Bone anti-resorptive compounds
04/24/2003WO2003033663A2 Rankl mimics and uses thereof
04/24/2003WO2003033661A2 Methods of using 279, a human g protein-coupled receptor
04/24/2003WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor
04/24/2003WO2003033659A2 Antisense modulation of matrix metalloproteinase 1 expression
04/24/2003WO2003033658A2 Neutrokine-alpha and neutrokine-alpha splice variant
04/24/2003WO2003033657A2 Antisense antiviral agent and method for treating ssrna viral infection
04/24/2003WO2003033655A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
04/24/2003WO2003033653A2 Affinity enhancement agents
04/24/2003WO2003033645A2 Synthetic peptides and dna sequences for treatment of multiple sclerosis
04/24/2003WO2003033644A2 Peptide useful in immunomodulation
04/24/2003WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
04/24/2003WO2003033534A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
04/24/2003WO2003033529A2 Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases
04/24/2003WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033526A2 Synthesis of cyclosporin analogs
04/24/2003WO2003033525A1 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
04/24/2003WO2003033524A2 Peptidyl ketones as inhibitors of dpiv
04/24/2003WO2003033522A1 Isolation of lectins
04/24/2003WO2003033519A2 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
04/24/2003WO2003033514A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
04/24/2003WO2003033513A1 Differentially expressed genes associated with obesity and type 2 diabetes
04/24/2003WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors
04/24/2003WO2003033031A1 Dosage form, device and methods of treatment
04/24/2003WO2003033027A2 Dendrimers for use in targeted delivery
04/24/2003WO2003033023A1 Drugs ameliorating hypo-hdl cholesterolemia
04/24/2003WO2003033017A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone
04/24/2003WO2003033016A1 Use of neurotrophic factors for treating neurodegenerative diseases and cancer
04/24/2003WO2003033015A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
04/24/2003WO2003033014A2 Novel use of pulmonary surfactant
04/24/2003WO2003033013A1 Use of aplidine for the treatment of pancreatic cancer
04/24/2003WO2003033012A1 Kahalalide compounds for use in cancer therapy
04/24/2003WO2003033011A2 Repetitive motifs from salivary proline rich proteins, mucin and collagen
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033009A2 Novel drug targets for arthritis
04/24/2003WO2003032992A1 Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism
04/24/2003WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
04/24/2003WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003WO2003032963A2 Method of reducing type 2 diabetes in high risk patients
04/24/2003WO2003032958A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent
04/24/2003WO2003032949A1 Novel cyclosporin analog microemulsion preconcentrates
04/24/2003WO2003032928A2 Therapeutic composition and use
04/24/2003WO2003032926A2 Compositions and methods for reversal of drug resistance
04/24/2003WO2003032925A2 Glycosulfopeptide inhibitors and methods of use thereof
1 ... 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 ... 3163